Life Science Investor Mandates
(Jan. 31 - Feb. 6
)
|
|
|
|
|
Invests Up to $50M in Life Science Companies Globally, Seeks Strong China Angle
|
|
Seeks to Invest in Disruptive Healthcare Technologies
|
|
Invests in Therapeutics and Medical Devices that Address Large Markets
|
|
Seeks Therapeutics & Diagnostics Companies in Oncology, Autoimmune Disease, Orphan/Rare Disease, etc.
|
|
|
 |
|
By Gregory Mannix, Vice President International Business Development, LSN
LSN's journey to spread the word about the first
RESI conference in Europe, taking place on March 25
th in Vienna has been a great success. With three Fundraising Boot Camps in France and Sweden, followed by one in Denmark tomorrow, it has been an exciting week! The reception of these boot camps has been amazing, with high attendance and a lot of good interaction with the companies.
The workshop emphasized the need to look beyond regional resources, and tap in to the global ecosystem of investors and strategic partners. Of course there are a myriad of challenges to overcome to successfully enter the global stage. It can be difficult, but necessary, to break out beyond normal protocol and be more aggressive in outreach to investors. It is important to remember that a fundraising executive has to go and actively chase the opportunities, they are not simply waiting to be caught...
|
|
Dennis Ford, CEO of LSN, at Copenhagen Bio Science Park |
|
 |
 |
RESI Europe Innovation Challenge Application Deadline: February 20th, 2019
|
By Karen Deyo, Investor Research Analyst, LSN
LSN's first RESI in Europe is rapidly approaching and
Early Bird pricing ends on February 8th! With Partnering launching on the
25th, take a sneak peek at some of the investors coming to RESI. Don't forget to register to have the opportunity to meet with some of these investors one-on-one! Do you want added exposure?
Apply to the Innovation Challenge, where you could be selected to present a poster in the exhibition hall at RESI, with additional exposure in the LSN Newsletter and the RESI Program Guide. The application deadline is
February 20th!
We hope to see you in Vienna on March 25th!
|
|
|
By Lucy Parkinson, VP of Investor Research, LSN
While raising early stage capital is vital to a life science startup's journey from the bench to the bedside, it's also important for entrepreneurs to make connections with potential strategic partners.
Big pharma licensing and M&A is the ultimate exit strategy for most biotech startups, and in taking an in-depth look at 2018's licensing deals, LSN found that the major pharmas are looking earlier than ever for promising new assets.
In addition to curating the LSN Investor Platform and organizing the
RESI Conference series, LSN also provides the LSN Company and Licensing Deals platforms, which provide information on life science activity all over the world.
Our Licensing Deals data includes any deal announced that includes a financial metric (such as an up-front or milestone payment).
Therefore it doesn't capture deals that are announced with no financial specifics, but it does provide a broad overview of current activity in the pharma dealmaking space.
So what happened in 2018?
The most stark point is that many deals were made very, very early...
|
|
|
|
|
|
|
Created & Produced by
|
 |
|
|
|
